With at least two-thirds of study participants showing increased recall IFNγ responses to antigens upon ex vivo treatment with anti-PD-1 or anti-PD-L1 antibodies, our findings suggested that antibodies targeting the PD-1 pathway may be considered as adjuvants to boost vaccine-induced immunity in HIV infection. This evidence concerns the gene IFNG and HIV infectious disease.